-
Ozempic? superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors
worldpharmanews
March 06, 2019
Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology.
-
Ozempic? superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors
worldpharmanews
March 06, 2019
Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology.
-
Study may explain why once-promising cancer drugs failed
worldpharmanews
January 29, 2019
Nearly two decades after a class of once-promising cancer drugs called MMP inhibitors mysteriously failed in clinical trials
-
Merck enters into an exclusive licensing agreement with Vertex
biospectrumasia
January 28, 2019
Merck, a leading science and technology company has announced that it has entered into an exclusive licensing agreement with Vertex Pharmaceuticals Incorporated
-
Drug cocktail turns off the juice to cancer cells
worldpharmanews
December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth - this was discovered by researchers from the University of Basel's Biozentrum two years ago.
-
Important pipelines in development of the Liver Cancer Drug
Weiyi
December 11, 2018
The angiogenesis inhibitors and immune checkpoint inhibitors are the directions of main liver cancer drugs in development, and the drug combinations are also in development.
-
CStone's anti-CTLA-4 antibody CS1002 filed for clinical trial approval in Australia
prnasia
January 02, 2018
CStone Pharmaceuticals (Suzhou) Co., Ltd. today announced that it has submitted an Investigational New Drug (IND) application to the Human Research Ethics Committee at Ashford Cancer Center in Australia
-
Novartis' Tasigna Wins FDA Nod for First and Only CML Therapy
biospace
December 28, 2017
Novartis?announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna??(nilotinib) US product label.
-
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castrat
biospace
December 26, 2017
Apalutamide is the First Agent Submitted for Approval to Treat Earlier Stage Castration-Resistant Prostate Cancer at High Risk for Metastasis
-
FGF inhibitors may provide a new way to treat high blood pressure
europeanpharmaceuticalreview
November 22, 2017
Drugs designed to halt cancer growth may offer a new way to control high blood pressure…
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
